Anti-CD38 therapy impairs SARS-CoV-2 vaccine response against alpha and delta variants in patients with multiple myeloma.

Blood · 2022 · PMC8674107 · PMID 34905598

Europe PMC DOI

hedged sentence

—

closest p

—

boldest claim

The sentences

a near-significant trendno p-value reported

Among patients with MM, anti-CD38 therapy further reduced nAb production against the alpha variant, with a near-significant trend for the delta variant ( Figure 1E ).

also in 290 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.